Definitions
from Wiktionary, Creative Commons Attribution/Share-Alike License.
- noun A
calcimimetic drug .
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word cinacalcet.
Examples
-
Under the Amgen agreement, Amgen will advance $145 million of Sensipar®/Mimpara® cinacalcet HCl royalties to NPS.
unknown title 2011
-
Sensipar, whose chemical name is cinacalcet hydrochloride, generated $320 million in U.S.
Amgen, Pfizer, Potter, ‘Golden Voice’: Intellectual Property - Bloomberg 2011
-
"The results from ADVANCE, coupled with recently published data, including an observational study showing that cinacalcet significantly improved all-cause and cardiovascular survival in dialysis patients (3), underscore the importance of completing the ongoing EVOLVE (EValuation Of Cinacalcet Therapy to Lower CardioVascular Events (TM)) trial, a global, randomised, placebo-controlled, double-blind study evaluating the impact of cinacalcet on mortality and cardiovascular events in dialysis patients," said
-
Floege J, Raggi P, Block GA, et al. Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients.
-
"Although the results for the primary endpoint were not statistically significant, the findings from ADVANCE further support the hypothesis that treatment with cinacalcet plus low doses of vitamin D may slow the progression of this marker of risk in patients on dialysis with SHPT."
-
ADVANCE studied 360 patients with SHPT and detectable CAC who were randomised to open label treatment with cinacalcet (30-180 mg/day) plus low-dose vitamin D (less than or equal to 2 ug IV paricalcitol equivalent/dialysis session) or to flexible vitamin D therapy.
-
Mean (95 percent CI) serum calcium decreased by 0.51 mg/dL (-0.65, -0.37) in the cinacalcet group but increased by 0.17 mg/dL
-
Urena P, Raggi P, Chertow G, et al. The effects of cinacalcet plus low-dose vitamin D on cardiac valve calcification in hemodialysis patients with secondary hyperparathyroidism.
-
NPS Pharmaceuticals Receives $38.4 Million for Sale of REGPARA Royalty Rights today announced the sale of its royalty rights from sales of REGPARA (R) (cinacalcet HCl)
-
(PTH, calcium, phosphorus) -- Safety and tolerability of cinacalcet
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.